Rick Wanstall Net Worth

The estimated Net Worth of Rick Wanstall is at least $147 Thousand dollars as of 25 May 2022. Mr. Wanstall owns over 3,777 units of Aileron Therapeutics Inc stock worth over $146,880 and over the last 6 years he sold ALRN stock worth over $0. In addition, he makes $0 as Chief Financial Officer and Treasurer at Aileron Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Wanstall ALRN stock SEC Form 4 insiders trading

Rick has made over 4 trades of the Aileron Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 3,777 units of ALRN stock worth $4,532 on 25 May 2022.

The largest trade he's ever made was buying 38,612 units of Aileron Therapeutics Inc stock on 12 May 2022 worth over $44,018. On average, Rick trades about 4,900 units every 1 days since 2019. As of 25 May 2022 he still owns at least 51,000 units of Aileron Therapeutics Inc stock.

You can see the complete history of Mr. Wanstall stock trades at the bottom of the page.

Rick Wanstall biography

Rick Wanstall serves as Chief Financial Officer, Treasurer of the Company. Effective September 13, 2019. he has served as the Company’s principal accounting officer since March 27, 2019 and has served as the Company’s Vice President, Finance and Operations since July 2018. From July 2014 to July 2018, Mr. Wanstall served as Vice President, Finance at Moderna Therapeutics, Inc., a biotechnology company focused on drug discovery and drug development based on messenger RNA. Prior to Moderna, Mr. Wanstall served as Senior Vice President, Global Finance at Stream Global Services, Inc., a multinational business process outsourcing company, from May 2010 to July 2014. Previously, Mr. Wanstall served in management roles in finance, accounting and SEC reporting for several technology and financial services companies. Mr. Wanstall began his career at Coopers & Lybrand, LLC. Mr. Wanstall received a B.A. from Salem State College, and a M.B.A. from Babson College.

How old is Rick Wanstall?

Rick Wanstall is 51, he's been the Chief Financial Officer and Treasurer of Aileron Therapeutics Inc since 2019. There are 8 older and 4 younger executives at Aileron Therapeutics Inc. The oldest executive at Aileron Therapeutics Inc is Nolan Sigal, 70, who is the Independent Director.

What's Rick Wanstall's mailing address?

Rick's mailing address filed with the SEC is C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE, MA, 02139.

Insiders trading at Aileron Therapeutics Inc

Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag..., and Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.

What does Aileron Therapeutics Inc do?

aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig

Complete history of Mr. Wanstall stock trades at Aileron Therapeutics Inc and Oncorus

Aileron Therapeutics Inc executives and stock owners

Aileron Therapeutics Inc executives and other stock owners filed with the SEC include:

• Manuel Aivado,
  President, Chief Executive Officer, Director
• Dr. Manuel C. Aivado,
  Pres, CEO & Director
• Dr. Vojislav Vukovic M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Vojislav Vukovic,
  Senior Vice President, Chief Medical Officer
• Richard J. Wanstall M.B.A.,
  SVP, CFO & Treasurer
• D. Allen Annis,
  Senior Vice President - Research
• Jeffrey Bailey,
  Chairman of the Board
• Rick Wanstall,
  Chief Financial Officer, Treasurer
• Jodie Morrison,
  Independent Director
• Reinhard Ambros,
  Lead Independent Director
• Josef von Rickenbach,
  Independent Director
• Nolan Sigal,
  Independent Director
• William McKee,
  Independent Director
• Dr. D. Allen Annis Ph.D.,
  Sr. VP of Research
• Alan A Musso,
  
• Allen Annis,
  SVP, Research
• 2008 Trust The Edward & Mic...,
  10% owner
• Edward M Elkin,
  Director
• Gary J Knauer,
  CFO, Treasurer & Secretary
• Glenda Baskin Glover,
  Director
• Joseph Looney,
  Director
• Peter Gutmann,
  Director
• Gary Gelman,
  Chairman, President & CEO
• Kira Nelson,
  See Remarks
• Donald Dougherty,
  SVP & Chief Financial Officer
• Caleb Maxfield Winder,
  Director
• Tree Partners Ii Annex, L...,
  10% owner
• Ib Investment Co., Ltd. Aju,
  10% owner
• Medical Fund Lp Gullans Ste...,
  
• Ltd. Kck,
  10% owner
• Llc Cvf,,
  10% owner
• John H Mcarthur,
  Director
• Joseph A., Iii Yanchik,
  See Remarks
• Armen Shanafelt,
  Director
• Brian M. Jr. Gallagher,
  Director
• Tree Partners Ii Lp Apple,
  10% owner
• Management Group, Llc Lilly...,
  
• Emerging Markets Ltd. Sigma,
  10% owner
• Jon B. Platt,
  10% owner
• Scott Kapnick,
  Director
• Bioventures Ltd Novartis Ag...,
  
• Kathryn Gregory,
  SVP, Chief Business Officer
• John P Phd Longenecker,
  President and CEO
• Muneer A Satter,
  See Remarks
• Vojo Vukovic,
  Chief Medical Officer
• William Fairey,
  
• James Brian Windsor,
  President and COO
• Of Texas/Texas Am Investmen...,
  10% owner